| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Lilly |
| Recipient: You |
| Company: Genentech |
| Recipient: You |
| Company: Janssen Oncology |
| Recipient: You |
| Company: ResistanceBio |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: Vial CRO |
| Recipient: You |
| Company: Anheart Therapeutics |
| Recipient: You |
| Company: Iovance Biotherapeutics |
| Recipient: You |
| Company: bristol-myers sqibb |
| Recipient: You |
| Company: Daiichi Sankyo |
| Recipient: You |
| Company: ConcertAI |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Loxo |
| Recipient: Your Institution |
| Company: Mirati Therapeutics |
| Recipient: Your Institution |
| Company: Anheart Therapeutics |
| Recipient: Your Institution |
| Company: Navire |
| Recipient: Your Institution |
| Company: Summit pharmaceuticals |
| Recipient: Your Institution |
| Company: Puma Biotechnology |
| Recipient: Your Institution |
| Company: Advenchen Laboratories |
| Recipient: Your Institution |
| Company: Seattle Genetics/Astellas |
| Recipient: Your Institution |
| Company: Inhibrix |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
|
| Open Payments URL: https://openpaymentsdata.cms.gov/physician/204570/summary |
|